Αρχική World News EMA Recommends Extension of Indications for Inotuzumab Ozogamicin World News EMA Recommends Extension of Indications for Inotuzumab Ozogamicin Από Ogkologos - 29 Απριλίου, 2026 257 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with... 11 Ιουνίου, 2026 Keto Molecule Offers Clue for Preventing Colorectal Cancer 2 Ιουνίου, 2022 Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... 24 Μαρτίου, 2021 For Advanced Prostate Cancer, Radiopharmaceutical Improves Survival 29 Ιουνίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone... Study Offers Insights on Health Problems among AYA Cancer Survivors Combination of Nivolumab and Ipilimumab Yields Better Outcomes Compared to Ipilimumab... Olaparib approved for 800 prostate and breast cancer patients in England